{"id":151,"date":"2025-05-13T11:10:13","date_gmt":"2025-05-13T09:10:13","guid":{"rendered":"https:\/\/blog.u-bourgogne.fr\/reglementation-des-medicaments-de-therapie-innovante\/?page_id=151"},"modified":"2025-10-08T11:49:20","modified_gmt":"2025-10-08T09:49:20","slug":"conference-program","status":"publish","type":"page","link":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/conference-program\/","title":{"rendered":"Conference Program"},"content":{"rendered":"<p><section class=\"kc-elm kc-css-448903 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-6245 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div data-kc-equalheight=\"true\" data-kc-row-action=\"true\" data-kc-equalheight-align=\"middle\" class=\"kc-elm kc-css-657069 kc_row kc_row_inner\"><div class=\"kc-elm kc-css-514223 kc_col-sm-3 kc_column_inner kc_col-sm-3\"><div class=\"kc_wrapper kc-col-inner-container\"><\/div><\/div><div class=\"kc-elm kc-css-685139 kc_col-sm-5 kc_column_inner kc_col-sm-5\"><div class=\"kc_wrapper kc-col-inner-container\"><\/div><\/div><div class=\"kc-elm kc-css-90727 kc_col-sm-4 kc_column_inner kc_col-sm-4\"><div class=\"kc_wrapper kc-col-inner-container\"><div class=\"kc-elm kc-css-196825\" style=\"height: 36px; clear: both; width:100%;\"><\/div><div class=\"kc-elm kc-css-110849 kc-raw-code\"><style>\r\n.french-button {\r\n  background-color: white;\r\n  color: #0055A4;\r\n  border: 2px solid #0055A4;\r\n  border-radius: 6px;\r\n  padding: 10px 15px;\r\n  font-weight: bold;\r\n  font-size: 16px;\r\n  cursor: pointer;\r\n  display: inline-flex;\r\n  align-items: center;\r\n  gap: 10px;\r\n}\r\n.french-button img {\r\n  width: 24px;\r\n  height: auto;\r\n}\r\n.french-button:hover {\r\n  background-color: #0055A4;\r\n  color: white;\r\n}\r\n<\/style>\r\n\r\n<a href=\"https:\/\/blog.u-bourgogne.fr\/reglementation-des-medicaments-de-therapie-innovante\/programme\/\">\r\n  <div class=\"french-button\">\r\n    <img decoding=\"async\" src=\"https:\/\/upload.wikimedia.org\/wikipedia\/en\/c\/c3\/Flag_of_France.svg\" alt=\"French flag\">\r\n    Acc\u00e9dez \u00e0 la version Fran\u00e7aise\r\n  <\/div>\r\n<\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-844975 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-356295 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-748779\" style=\"height: 49px; clear: both; width:100%;\"><\/div><div class=\"kc-elm kc-css-258296 kc_shortcode kc_single_image\">\n\n        <img decoding=\"async\" src=\"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-content\/uploads\/sites\/213\/2025\/06\/AdobeStock_1182787170.png\" class=\"\" alt=\"\" \/>    <\/div>\n<div class=\"kc-elm kc-css-161343\" style=\"height: 49px; clear: both; width:100%;\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-849515 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-185155 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-410379 kc-title-wrap \">\n\n\t<h1 class=\"kc_title\">Conference Program<\/h1>\n<\/div>\n<\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-419935 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-938847 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-14806 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"et-clock\"><\/i>\t<\/div>\n<\/div>\n\n<div class=\"kc-elm kc-css-402355 kc-title-wrap \">\n\n\t<h2 class=\"kc_title\">Thursday, 9 October 2025 \u2014 Day 1:\r\nLegal, regulatory and institutional framework<\/h2>\n<\/div>\n\n<div class=\"kc-elm kc-css-530705 divider_line\">\n\t<div class=\"divider_inner divider_line1\">\n\t\t\t<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-971867 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-727050 kc_col-sm-6 kc_column kc_col-sm-6\"><div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-988321 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\">Morning \u2013 Part 1: Regulatory framework of ATMPs and international comparisons<\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-195522 kc_text_block\"><\/p>\n<p>8h45: Wellcoming participants<\/p>\n<p>9h15: Opening session<\/p>\n<p>\ud83d\udc68\u200d\u2696\ufe0f <strong>Chair<\/strong>: Isabelle Poirot-Maz\u00e8res, Full Professor, President of AFDS, Universit\u00e9 Toulouse Capitole <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-231107 kc_text_block\"><\/p>\n<p>\ud83c\udfaf\u00a0<strong>Objective<\/strong>: Explore the specificities of the regulatory framework in Europe and compare with other regions. Discuss the necessary adjustments and challenges related to international regulation.<\/p>\n<p>\n<\/div><\/div><\/div><div class=\"kc-elm kc-css-208417 kc_col-sm-6 kc_column kc_col-sm-6\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-908168 kc_text_block\"><\/p>\n<p>9:30 <em>The contributions of the pharmaceutical package in the field of ATMPs: between the new definition of gene therapy medicinal products and regulatory sandboxes?<\/em><br data-start=\"158\" data-end=\"161\">\ud83c\udf93 <strong>Mathieu Guerriaud<\/strong>, Full Professor, UBE \u2013 AEDEP, EAHL, CREDIMI <img decoding=\"async\" draggable=\"false\" role=\"img\" class=\"emoji\" alt=\"\ud83c\uddeb\ud83c\uddf7\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\"><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-929004 kc_text_block\"><\/p>\n<p>9:50 <em>The Regulation of ATMPs in the USA: What Differences with the EU?<\/em><br data-start=\"1025\" data-end=\"1028\"><span class=\"_fadeIn_m1hgl_8\">\ud83c\udf93 <\/span><strong data-start=\"1033\" data-end=\"1050\"><span class=\"_fadeIn_m1hgl_8\">Erika <\/span><span class=\"_fadeIn_m1hgl_8\">Lietzan<\/span><\/strong><span class=\"_fadeIn_m1hgl_8\">, <\/span><span class=\"_fadeIn_m1hgl_8\">Full Professor<\/span><span class=\"_fadeIn_m1hgl_8\">, <\/span><span class=\"_fadeIn_m1hgl_8\">Missouri <\/span><span class=\"_fadeIn_m1hgl_8\">University <img decoding=\"async\" draggable=\"false\" role=\"img\" class=\"emoji\" alt=\"\ud83c\uddfa\ud83c\uddf8\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1fa-1f1f8.svg\"><\/span><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-67495 kc_text_block\"><\/p>\n<p><span class=\"_fadeIn_m1hgl_8\">10:10 <\/span><em data-start=\"956\" data-end=\"1025\"><span class=\"_fadeIn_m1hgl_8\">T<\/span>he Reality of the Regulatory Framework for ATMPs<\/em><br data-start=\"1025\" data-end=\"1028\"><span class=\"_fadeIn_m1hgl_8\">\ud83c\udfe5 <strong>Heloise\u00a0<\/strong><\/span><strong><span class=\"_fadeIn_m1hgl_8\">Mignot <\/span><\/strong><strong><span class=\"_fadeIn_m1hgl_8\">EMA<\/span><\/strong> <span class=\"_fadeIn_m1hgl_8\"><img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1ea-1f1fa.svg\" alt=\"\ud83c\uddea\ud83c\uddfa\"><\/span><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-42492 kc_text_block\"><\/p>\n<p><span class=\"_fadeIn_m1hgl_8\">10h30 Discussion and break<\/span><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-625566 kc_text_block\"><\/p>\n<p>11:00\u00a0<em data-start=\"1136\" data-end=\"1221\">How can competition law regulate mergers in biotech companies producing ATMPs?<\/em><br data-start=\"204\" data-end=\"207\">\ud83c\udf93 <strong>Clotilde Fortier<\/strong>, Full Professor, Directress of Credimi, UBE <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\"><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-290217 kc_text_block\"><\/p>\n<p>11:20 <em data-start=\"1261\" data-end=\"1329\">CRISPR and GMO Regulation: Navigating the Intersection of Biotechnology, Public Health, and Legal Frameworks<\/em><br data-start=\"65\" data-end=\"68\" \/>\ud83c\udf93 <strong>Alessandro Nato<\/strong>, Postdoctoral Researcher Universit\u00e0 di Teramo &#038; Luiss Roma <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1ee-1f1f9.svg\" alt=\"\ud83c\uddee\ud83c\uddf9\" \/><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-506611\" style=\"height: 20px; clear: both; width:100%;\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-347062 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-200395 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-630733 divider_line\">\n\t<div class=\"divider_inner divider_line1\">\n\t\t\t<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-936530 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-550775 kc_col-sm-6 kc_column kc_col-sm-6\"><div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-486401 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\">Afternoon \u2013 Part 2: Specific issues and legal liability<\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-191348 kc_text_block\"><\/p>\n<p>\ud83d\udc68\u200d\u2696\ufe0f <strong>Chair<\/strong><span class=\"_fadeIn_m1hgl_8\">: Olivier Debarge, Full Professor, President of AEDEP<\/span>\u00a0\ud83c\uddeb\ud83c\uddf7<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-342383 kc_text_block\"><\/p>\n<p>\ud83c\udfaf <strong>Objective<\/strong>: Identify specific legal challenges related to ATMPs: liability of actors, regulation of cross-border circuits, tensions between commercial logic and ethical principles.<\/p>\n<p>\n<\/div><\/div><\/div><div class=\"kc-elm kc-css-963714 kc_col-sm-6 kc_column kc_col-sm-6\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-769052 kc_text_block\"><\/p>\n<p>14:00 <em data-start=\"1647\" data-end=\"1712\">What legal liability arises in case of ATMP failure?<\/em><br data-start=\"52\" data-end=\"55\" \/>\ud83c\udf93 <strong>Val\u00e9rie Siranyan<\/strong>, Full Professor,\u00a0<span style=\"font-style: inherit;\">Universit\u00e9\u00a0<\/span><span style=\"font-style: inherit;\">Lyon 1 Claude Bernard \u2013 AEDEP <\/span><img decoding=\"async\" class=\"emoji\" style=\"background-color: #ffffff; font-style: inherit;\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-176713 kc_text_block\"><\/p>\n<p>14:20 <em data-start=\"1772\" data-end=\"1856\">Manufacturing ATMPs and cross-border travel of cells: what challenges?<\/em><br data-start=\"70\" data-end=\"73\" \/>\ud83c\udf93 <strong>Tamara Hervey<\/strong>, Full Professor, City Univ. London \ud83c\uddec\ud83c\udde7<br data-start=\"129\" data-end=\"132\" \/>\ud83c\udf93 <strong>Mirko Dukovic<\/strong>, Postdoctoral Researcher \ud83c\uddf2\ud83c\uddea \/ Hertie School \ud83c\udde9\ud83c\uddea<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-816227 kc_text_block\"><\/p>\n<p>14:40<i>\u00a0Discussion<\/i><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-169775 kc_text_block\"><\/p>\n<p>15:00 <em data-start=\"1952\" data-end=\"2008\">Development of the ATMP market: risk or opportunity for consumer law?<\/em><br \/>\ud83c\udf93 <strong>Guillaume Rousset<\/strong>, Full Professor, Director of CRDMS, Universit\u00e9 Lyon 3 Jean Moulin\u00a0<img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-194532 kc_text_block\"><\/p>\n<p>15:20 <em data-start=\"2073\" data-end=\"2144\">The non-commercialisation of human body elements (SoHO) and ATMPs<\/em><br \/>\ud83c\udf93 <strong>Isabelle Moine-Dupuis<\/strong>, Associate Professor with HDR, Dijon \ud83c\uddeb\ud83c\uddf7<br \/>\ud83e\ude78 <strong>Jean-Baptiste Thibert<\/strong>, Director of EFS Rennes \ud83c\uddeb\ud83c\uddf7<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-23670 kc_text_block\"><\/p>\n<div class=\"kc-elm kc-css-113387 kc_text_block\">\n<p><span class=\"_fadeIn_m1hgl_8\">15:40 Discussion and break<\/span><\/p>\n<\/div>\n<p>\n<\/div><div class=\"kc-elm kc-css-77639 kc_text_block\"><\/p>\n<div class=\"kc-elm kc-css-80574 kc_text_block\">\n<p>16:15 Award ceremony for the 2025 AFDS health law thesis prize (Prix Jean-Marie Auby), presented by the Bullukian Foundation.\u00a0<\/p>\n<\/div>\n<p>\n<\/div><div class=\"kc-elm kc-css-134005 kc_text_block\"><\/p>\n<div class=\"kc-elm kc-css-113387 kc_text_block\">\u00a0<\/div>\n<div class=\"kc-elm kc-css-861794 kc_text_block\">\n<p>17:00 End of the first day.<\/p>\n<\/div>\n<p>\n<\/div><\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-585631 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-257693 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-419053\" style=\"height: 53px; clear: both; width:100%;\"><\/div>\n<div class=\"kc-elm kc-css-204722 divider_line\">\n\t<div class=\"divider_inner divider_line2\">\n\t\t<i class=\"et-clock\"><\/i>\t<\/div>\n<\/div>\n\n<div class=\"kc-elm kc-css-942627 kc-title-wrap \">\n\n\t<h2 class=\"kc_title\">Friday, 10 October 2025\r\nDay 2 \u2013 Innovation, competition and economic challenges<\/h2>\n<\/div>\n\n<div class=\"kc-elm kc-css-248321 divider_line\">\n\t<div class=\"divider_inner divider_line1\">\n\t\t\t<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-45228 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-858156 kc_col-sm-6 kc_column kc_col-sm-6\"><div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-454860 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\">Morning \u2013 Part 3: Patients\u2019 rights and societal challenges\r\n<\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-21197 kc_text_block\"><\/p>\n<p>\ud83d\udc68\u200d\u2696\ufe0f <strong>Chair<\/strong>: Didier Truchet, Professor Emeritus, Universit\u00e9 Paris 2 Panth\u00e9on-Assas \u2013 Honorary President of AFDS <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-514137 kc_text_block\"><\/p>\n<p>\ud83c\udfaf <strong>Objective<\/strong>: Examine the consequences of ATMPs on patients\u2019 rights (consent, access, prioritisation) and analyse how these therapies are perceived in society, including beyond the healthcare sphere.<\/p>\n<p>\n<\/div><\/div><\/div><div class=\"kc-elm kc-css-733799 kc_col-sm-6 kc_column kc_col-sm-6\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-358214 kc_text_block\"><\/p>\n<p>9:00 <em data-start=\"2581\" data-end=\"2647\">From innovation to patient rights: navigating informed consent and patient protection for ATMPs<\/em><br data-start=\"52\" data-end=\"55\" \/>\ud83c\udf93<strong> Laura Kadile<\/strong>, Assistant Professor, University of Riga \ud83c\uddf1\ud83c\uddfb<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-66062 kc_text_block\"><\/p>\n<p>9:20 <em data-start=\"1952\" data-end=\"2008\">ATMPs and their challenges, the perspective of an industry representative (Gilead)<\/em><br data-start=\"82\" data-end=\"85\" \/>\ud83d\udcbc<strong> Pierre Sinet<\/strong>, Industrial Pharmacist \ud83c\uddeb\ud83c\uddf7<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-608145 kc_text_block\"><\/p>\n<p>9:40 <em>Discussion<\/em><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-962585 kc_text_block\"><\/p>\n<p>10:00 <em data-start=\"497\" data-end=\"617\">Hospital accessibility of ATMPs in France: cross-analysis of consumption data and the regulatory framework<\/em><br data-start=\"106\" data-end=\"109\" \/>\ud83c\udf93 <strong>Blandine Juillard-Condat<\/strong>, Assistant Professor and Hospital Pharmacist, Universit\u00e9 de Toulouse 3 Paul Sabatier \u2013 CERPOP &#038; IRDES &#8211; AEDEP\u00a0<img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-501105 kc_text_block\"><\/p>\n<p>10:40 Discussion and break<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-162495 kc_text_block\"><\/p>\n<p>11:00 <em data-start=\"2073\" data-end=\"2144\">Misuse of ATMPs: genetic doping? Myth or reality?<\/em><br data-start=\"49\" data-end=\"52\" \/>\ud83c\udf93 <strong>C\u00e9cile Chaussard<\/strong>, Associate Professor with HDR, UBE \ud83c\uddeb\ud83c\uddf7<br data-start=\"111\" data-end=\"114\" \/>\ud83c\udf93 <strong>Claire Sourzat<\/strong>, Associate Professor, UBE \ud83c\uddeb\ud83c\uddf7<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-49984 kc_text_block\"><\/p>\n<p>11:30 Discussion and Lunch<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-879691\" style=\"height: 20px; clear: both; width:100%;\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-593193 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-822926 kc_col-sm-12 kc_column kc_col-sm-12\"><div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-192141 divider_line\">\n\t<div class=\"divider_inner divider_line1\">\n\t\t\t<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/section><section class=\"kc-elm kc-css-393827 kc_row\"><div class=\"kc-row-container  kc-container\"><div class=\"kc-wrap-columns\"><div class=\"kc-elm kc-css-931236 kc_col-sm-6 kc_column kc_col-sm-6\"><div class=\"kc-col-container\">\n<div class=\"kc-elm kc-css-643773 kc-title-wrap \">\n\n\t<h3 class=\"kc_title\">Afternoon \u2013 Part 4: The subtle balance between intellectual property protection, health economics, and patients' interests<\/h3>\n<\/div>\n<div class=\"kc-elm kc-css-961866 kc_text_block\"><\/p>\n<p>\ud83d\udc68\u200d\u2696\ufe0f <strong>Chair<\/strong><span class=\"_fadeIn_m1hgl_8\">: Olivier Debarge, Full Professor, President of AEDEP<\/span>\u00a0\ud83c\uddeb\ud83c\uddf7<\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-503226 kc_text_block\"><\/p>\n<p>\ud83c\udfaf Objective: Debate the protection of innovation, funding models for ATMPs, and the practical conditions for equitable access for patients.<\/p>\n<p>\n<\/div><\/div><\/div><div class=\"kc-elm kc-css-62325 kc_col-sm-6 kc_column kc_col-sm-6\"><div class=\"kc-col-container\"><div class=\"kc-elm kc-css-922488 kc_text_block\"><\/p>\n<h4>14:00 Round Table 1: <em>IP and patentability (cells, DNA, biosimilars)<\/em><\/h4>\n<p><span style=\"font-size: 12pt;\"><span style=\"font-style: inherit;\">\ud83d\udcbc <\/span><strong style=\"font-style: inherit;\">St\u00e9phane Oudin,<\/strong><span style=\"font-style: inherit;\"> PhD, Industrial Property Attorneys <\/span><img decoding=\"async\" class=\"emoji\" style=\"background-color: #ffffff; font-style: inherit;\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/span><\/p>\n<p>\ud83d\udcbc <strong>Matthieu Dhenne,<\/strong> PhD, Lawyer, Member of the Paris Bar <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-626811 kc_text_block\"><\/p>\n<h4 data-start=\"286\" data-end=\"386\">14:30 Round Table 2: <em>Financing access \/ reimbursing innovations \u2013 economic sustainability<\/em><\/h4>\n<p data-start=\"87\" data-end=\"127\">\ud83d\udcc8 <strong>Val\u00e9rie Paris<\/strong>, Economist, OECD <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p data-start=\"129\" data-end=\"182\">\ud83c\udf93 <strong>R\u00e9mi Pellet<\/strong>, Full Professor, Universit\u00e9\u00a0<span style=\"font-style: inherit;\">Paris Cit\u00e9 &#8211;\u00a0<\/span><span style=\"font-style: inherit;\">Paris 5 \u2013\u00a0<\/span><span style=\"font-style: inherit;\">v<\/span><span style=\"font-style: inherit;\">ice President of\u00a0<\/span><span style=\"font-style: inherit;\">AFDS <\/span><img decoding=\"async\" class=\"emoji\" style=\"background-color: #ffffff; font-style: inherit;\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p data-start=\"240\" data-end=\"276\" data-is-last-node=\"\" data-is-only-node=\"\">\u2696\ufe0f <strong>Blanka Bartos<\/strong>, Doctor of Law <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1ed-1f1fa.svg\" alt=\"\ud83c\udded\ud83c\uddfa\" \/><\/p>\n<p>\n<\/div><div class=\"kc-elm kc-css-107220 kc_text_block\"><\/p>\n<h4 data-start=\"0\" data-end=\"36\">15:00 Round Table 3: <em>The patient pathway<\/em><\/h4>\n<p data-start=\"38\" data-end=\"98\">\u2696\ufe0f <strong>Maxence Cormier<\/strong>, Associate Lecturer, Lawyer \u2013 AFDS <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p data-start=\"100\" data-end=\"130\">\ud83d\udcbc <strong>Pierre Sinet<\/strong>, Gilead <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p data-start=\"132\" data-end=\"200\">\ud83c\udfe5 <strong>Am\u00e9lie Cransac, <\/strong>Assistant Professor and Hospital Pharmacist, UBE CHU Dijon <img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/svg\/1f1eb-1f1f7.svg\" alt=\"\ud83c\uddeb\ud83c\uddf7\" \/><\/p>\n<p>\n<\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n","protected":false},"excerpt":{"rendered":"<p class=\"more-link-p\"><a class=\"btn btn-primary\" href=\"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/conference-program\/\">Voir plus &rarr;<\/a><\/p>\n","protected":false},"author":1137,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-151","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-json\/wp\/v2\/pages\/151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-json\/wp\/v2\/users\/1137"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-json\/wp\/v2\/comments?post=151"}],"version-history":[{"count":38,"href":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-json\/wp\/v2\/pages\/151\/revisions"}],"predecessor-version":[{"id":329,"href":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-json\/wp\/v2\/pages\/151\/revisions\/329"}],"wp:attachment":[{"href":"https:\/\/blog.ube.fr\/reglementation-des-medicaments-de-therapie-innovante\/wp-json\/wp\/v2\/media?parent=151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}